A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: LY3462817 (IV)
Drug: LY3462817 (SC)
Drug: Placebo (IV)
Drug: Placebo (SC)

Study type

Interventional

Funder types

Industry

Identifiers

NCT05440136
18141
J1A-MC-KDAE (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.

Enrollment

33 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation
  • Japanese participants must be first generation Japanese and have a body mass index (BMI) of 18.0 to 30.0 kilograms per square meter (kg/m²) (inclusive), and a body weight of 45 and 85 kg (inclusive)
  • Non-Japanese participants have a BMI of 18.0 to 32.0 kg/m² (inclusive), and a minimum body weight of 45 kg
  • Are males who agree to follow contraception requirements or females not of childbearing potential
  • Have blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have cancer or a malignant disease in the past 5 years
  • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Are unwilling to receive study drug administration by injections or through the veins

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

33 participants in 4 patient groups, including a placebo group

LY3462817 - SC
Experimental group
Description:
LY3462817 administered subcutaneously (SC)
Treatment:
Drug: LY3462817 (SC)
LY3462817 - IV
Experimental group
Description:
LY3462817 administered intravenously (IV)
Treatment:
Drug: LY3462817 (IV)
Placebo - SC
Placebo Comparator group
Description:
Placebo administered SC
Treatment:
Drug: Placebo (SC)
Placebo - IV
Placebo Comparator group
Description:
Placebo administered IV
Treatment:
Drug: Placebo (IV)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems